# Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

> **NCT02555657** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 622 (actual)

## Conditions studied

- Metastatic Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** capecitabine
- **DRUG:** eribulin
- **DRUG:** gemcitabine
- **DRUG:** vinorelbine

## Key facts

- **NCT ID:** NCT02555657
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-13
- **Primary completion:** 2019-04-11
- **Final completion:** 2020-11-10
- **Target enrollment:** 622 (ACTUAL)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555657, "Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02555657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*